Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study.
Fiche publication
Date publication
février 2018
Journal
Targeted oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Mme POZET Astrid
Tous les auteurs :
Zaanan A, Palle J, Soularue E, Leroy F, Louafi S, Tougeron D, Manfredi S, Artru P, Pozet A, Taieb J
Lien Pubmed
Résumé
Trastuzumab with fluoropyrimidine and cisplatin is the standard first-line treatment in patients with HER2-positive advanced gastro-esophageal adenocarcinoma. However, there are no safety and efficacy data of trastuzumab with FOLFIRI.
Référence
Target Oncol. 2018 Feb;13(1):107-112